Skip to main content

Breast Cancer Research

Ausgabe 1/2013

Inhalt (25 Artikel)

Viewpoint

Visualizing movement in the tumor microenvironment landscape

Veronica Calvo, Paraic A Kenny

Review

Patient-derived breast tumor xenografts facilitating personalized cancer therapy

Melissa D Landis, Brian D Lehmann, Jennifer A Pietenpol, Jenny C Chang

Open Access Research article

Hypoxia stimulates migration of breast cancer cells via the PERK/ATF4/LAMP3-arm of the unfolded protein response

Anika Nagelkerke, Johan Bussink, Hilda Mujcic, Bradly G Wouters, Steffi Lehmann, Fred CGJ Sweep, Paul N Span

Open Access Research article

Comparison of percent density from raw and processed full-field digital mammography data

Celine M Vachon, Erin EE Fowler, Gail Tiffenberg, Christopher G Scott, V Shane Pankratz, Thomas A Sellers, John J Heine

Open Access Research article

Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer

Kelly K Hunt, Hannah Wingate, Tomoya Yokota, Yanna Liu, Gordon B Mills, Fan Zhang, Bingliang Fang, Chun-Hui Su, Ming Zhang, Min Yi, Khandan Keyomarsi

Open Access Research article

Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening

Vera Kloten, Birte Becker, Kirsten Winner, Michael G Schrauder, Peter A Fasching, Tobias Anzeneder, Jürgen Veeck, Arndt Hartmann, Ruth Knüchel, Edgar Dahl

Open Access Research article

The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer

Emmi Peurala, Peppi Koivunen, Kirsi-Maria Haapasaari, Risto Bloigu, Arja Jukkola-Vuorinen

Open Access Research article

RhoB modifies estrogen responses in breast cancer cells by influencing expression of the estrogen receptor

Claire Médale-Giamarchi, Isabelle Lajoie-Mazenc, Emilie Malissein, Elise Meunier, Bettina Couderc, Yann Bergé, Thomas Filleron, Laura Keller, Claudine Marty, Magali Lacroix-Triki, Florence Dalenc, Sophie F Doisneau-Sixou, Gilles Favre

Open Access Research article

Mammographic density as a predictor of breast cancer survival: the Multiethnic Cohort

Gertraud Maskarinec, Ian S Pagano, Melissa A Little, Shannon M Conroy, Song-Yi Park, Laurence N Kolonel

Open Access Research article

Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models

Amine Issa, Jason W Gill, Marinus R Heideman, Ozgur Sahin, Stefan Wiemann, Julien H Dey, Nancy E Hynes

Viewpoint

A functional link between FOXA1 and breast cancer SNPs

Madhumohan R Katika, Antoni Hurtado

Viewpoint

Unraveling the 'TGF-β paradox' one metastamir at a time

Danny R Welch, Douglas R Hurst

Open Access Research article

Hormone-sensing cells require Wip1 for paracrine stimulation in normal and premalignant mammary epithelium

Gerard A Tarulli, Duvini De Silva, Victor Ho, Kamini Kunasegaran, Kakaly Ghosh, Bryan C Tan, Dmitry V Bulavin, Alexandra M Pietersen

Open Access Research article

Mammographic density and risk of breast cancer according to tumor characteristics and mode of detection: a Spanish population-based case-control study

Marina Pollán, Nieves Ascunce, María Ederra, Alberto Murillo, Nieves Erdozáin, Jose Enrique Alés-Martínez, Roberto Pastor-Barriuso

Open Access Research article

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer

Carsten Denkert, Jens Huober, Sibylle Loibl, Judith Prinzler, Ralf Kronenwett, Silvia Darb-Esfahani, Jan C Brase, Christine Solbach, Keyur Mehta, Peter A Fasching, Bruno V Sinn, Knut Engels, Mattea Reinisch, Martin-Leo Hansmann, Hans Tesch, Gunter von Minckwitz, Michael Untch

Open Access Research article

Anti-matrix metalloproteinase-9 DNAzyme decreases tumor growth in the MMTV-PyMT mouse model of breast cancer

Miranda A Hallett, Bin Teng, Hisashi Hasegawa, Luciana P Schwab, Tiffany N Seagroves, Tayebeh Pourmotabbed

Open Access Research article

Optical imaging correlates with magnetic resonance imaging breast density and revealscomposition changes during neoadjuvant chemotherapy

Thomas D O'Sullivan, Anaïs Leproux, Jeon-Hor Chen, Shadfar Bahri, Alex Matlock, Darren Roblyer, Christine E McLaren, Wen-Pin Chen, Albert E Cerussi, Min-Ying Su, Bruce J Tromberg

Open Access Research article

Circulating levels of 25-hydroxyvitamin D and risk of breast cancer: a nested case-control study

Stephanie Scarmo, Yelena Afanasyeva, Per Lenner, Karen L Koenig, Ronald L Horst, Tess V Clendenen, Alan A Arslan, Yu Chen, Göran Hallmans, Eva Lundin, Sabina Rinaldi, Paolo Toniolo, Roy E Shore, Anne Zeleniuch-Jacquotte

Open Access Research article

Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer

Siver A Moestue, Cornelia G Dam, Saurabh S Gorad, Alexandr Kristian, Anna Bofin, Gunhild M Mælandsmo, Olav Engebråten, Ingrid S Gribbestad, Geir Bjørkøy

Open Access Research article

Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families

Zhi L Teo, Daniel J Park, Elena Provenzano, Catherine A Chatfield, Fabrice A Odefrey, Tu Nguyen-Dumont, James G Dowty, John L Hopper, Ingrid Winship, David E Goldgar, Melissa C Southey

Open Access Research article

Breast cancer in women using digoxin: tumor characteristics and relapse risk

Robert J Biggar, Elisabeth W Andersen, Niels Kroman, Jan Wohlfahrt, Mads Melbye

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.